MCF Advisors’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-42,854
| Closed | -$411K | – | 1037 |
|
|
2024
Q4 | $411K | Sell |
42,854
-204,170
| -83% | -$1.07M | 0.03% | 159 |
|
|
2024
Q3 | $706K | Hold |
247,024
| – | – | 0.05% | 112 |
|
|
2024
Q2 | $721K | Hold |
247,024
| – | – | 0.05% | 108 |
|
|
2024
Q1 | $788K | Hold |
247,024
| – | – | 0.06% | 102 |
|
|
2023
Q4 | $830K | Buy |
247,024
+204,170
| +476% | +$526K | 0.07% | 96 |
|
|
2023
Q3 | $102K | Hold |
42,854
| – | – | 0.01% | 285 |
|
|
2023
Q2 | $75.4K | Hold |
42,854
| – | – | 0.01% | 316 |
|
|
2023
Q1 | $132K | Hold |
42,854
| – | – | 0.01% | 246 |
|
|
2022
Q4 | $227K | Sell |
42,854
-9,000
| -17% | -$41.1K | 0.02% | 198 |
|
|
2022
Q3 | $183K | Sell |
51,854
-7,805
| -13% | -$25.8K | 0.02% | 206 |
|
|
2022
Q2 | $154K | Buy |
59,659
+2,190
| +4% | +$6.09K | 0.02% | 207 |
|
|
2022
Q1 | $257K | Buy |
+57,469
| New | +$259K | 0.02% | 166 |
|
|
2021
Q4 | – | Sell |
-66,185
| Closed | -$482K | – | 724 |
|
|
2021
Q3 | $482K | Buy |
66,185
+29,431
| +80% | +$253K | 0.05% | 104 |
|
|
2021
Q2 | $368K | Hold |
36,754
| – | – | 0.04% | 119 |
|
|
2021
Q1 | $351K | Buy |
+36,754
| New | +$360K | 0.04% | 116 |
|
|
2020
Q4 | – | Sell |
-45,833
| Closed | -$407K | – | 490 |
|
|
2020
Q3 | $407K | Buy |
+45,833
| New | +$522K | 0.05% | 85 |
|
Other funds holding PSTX
MCF Advisors's PSTX Position: Q1 2025 in Review
MCF Advisors sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 42,854 shares — an estimated $411K sold.
MCF Advisors first reported a position in PSTX in Q3 2020 and held it in 16 quarters. The position peaked at $830K in Q4 2023. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- MCF Advisors reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- MCF Advisors sold 42,854 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $411K.
- MCF Advisors first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 16 quarters.
- MCF Advisors's Poseida Therapeutics, Inc. Common Stock position peaked at $830K in Q4 2023.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on MCF Advisors's 13F filing for Q1 2025, filed 6 May 2025.